Neurocrine confirms it is to acquire Soleno Therapeutics (SLNO) for USD 53/shr in cash or USD 2.9bln
Context
Neurocrine's acquisition of Soleno Therapeutics for USD 53 per share highlights its strategic move to bolster its portfolio, with a total transaction value of USD 2.9 billion. This deal could signal confidence in revenue growth potential and may influence market perceptions regarding the health sector's M&A activity, potentially impacting peer valuations and investor sentiment in biotechnology.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#METALS#EU SESSION#US SESSION#METALS & MINING#DXY#US EQUITIES